Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
Abstract Background Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of i...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-019-0500-x |
id |
doaj-b1d97f23960b4686b2ea7c7bf4330c71 |
---|---|
record_format |
Article |
spelling |
doaj-b1d97f23960b4686b2ea7c7bf4330c712020-11-25T02:30:47ZengBMCJournal of Ovarian Research1757-22152019-03-0112111110.1186/s13048-019-0500-xMetabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot studyJacopo Troisi0Claudia Cinque1Luigi Giugliano2Steven Symes3Sean Richards4David Adair5Pierpaolo Cavallo6Laura Sarno7Giovanni Scala8Maria Caiazza9Maurizio Guida10Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoDepartment of Chemistry and Physics, University of Tennessee at ChattanoogaDepartment of Obstetrics and Gynecology, University of Tennessee College of MedicineDepartment of Obstetrics and Gynecology, University of Tennessee College of MedicineDepartment of Physics, University of SalernoDepartment of Neurosciences and Reproductive and Dentistry Sciences, University of Naples Federico IITheoreo srl, Via degli Ulivi 3Azienda Sanitaria Locale, distretto sanitario 66Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoAbstract Background Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered, .http://link.springer.com/article/10.1186/s13048-019-0500-xPolycystic ovary syndromeInositols-glucomannan associationMetabolomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jacopo Troisi Claudia Cinque Luigi Giugliano Steven Symes Sean Richards David Adair Pierpaolo Cavallo Laura Sarno Giovanni Scala Maria Caiazza Maurizio Guida |
spellingShingle |
Jacopo Troisi Claudia Cinque Luigi Giugliano Steven Symes Sean Richards David Adair Pierpaolo Cavallo Laura Sarno Giovanni Scala Maria Caiazza Maurizio Guida Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study Journal of Ovarian Research Polycystic ovary syndrome Inositols-glucomannan association Metabolomics |
author_facet |
Jacopo Troisi Claudia Cinque Luigi Giugliano Steven Symes Sean Richards David Adair Pierpaolo Cavallo Laura Sarno Giovanni Scala Maria Caiazza Maurizio Guida |
author_sort |
Jacopo Troisi |
title |
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
title_short |
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
title_full |
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
title_fullStr |
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
title_full_unstemmed |
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
title_sort |
metabolomic change due to combined treatment with myo-inositol, d-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
publisher |
BMC |
series |
Journal of Ovarian Research |
issn |
1757-2215 |
publishDate |
2019-03-01 |
description |
Abstract Background Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered, . |
topic |
Polycystic ovary syndrome Inositols-glucomannan association Metabolomics |
url |
http://link.springer.com/article/10.1186/s13048-019-0500-x |
work_keys_str_mv |
AT jacopotroisi metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT claudiacinque metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT luigigiugliano metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT stevensymes metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT seanrichards metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT davidadair metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT pierpaolocavallo metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT laurasarno metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT giovanniscala metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT mariacaiazza metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy AT maurizioguida metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy |
_version_ |
1724827950857060352 |